Skip to main content

Outlook Therapeutics, Inc.

OTLK
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001649989

In the last 90 days, Outlook Therapeutics, Inc. insiders filed 4 open-market purchases and 0 sales; 68 institutions reported holding it in 13F filings for Q2 2026, worth $32.2M in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding Outlook Therapeutics, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of OTLK: Q2 2022 compared with Q3 2022
MeasureQ2 2022Of which not filed for Q3 2022Q3 2022Change
Holders76176+1
Shares24.8M7.47K24.0M−768.4K (−3.1%)
Value$25.3M$8.00K$29.3M+$4.02M (+15.9%)

1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (6)

Institutions that held Outlook Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to OTLK in Q3 2022
InstitutionSharesValue% of portfolio
Susquehanna International Group, LLP35,904$44.0K0.00%
Squarepoint Ops LLC32,097$39.0K0.00%
PVG Asset Management Corp16,455$20.1K0.08%
D. E. Shaw & Co., Inc.10,599$13.0K0.00%
Jane Street Group, LLC10,561$13.0K0.00%
F/M Investments LLC10,000$12.0K0.02%

Sold out (5)

Institutions that held Outlook Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.

Institutions that sold out of OTLK in Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
AQR Capital Management LLC52,041$53.0K
Virtu Financial LLC21,119$22.0K
HRT Financial LP20,116$20.0K
Endurance Wealth Management, Inc.15,000$15.0K
UBS Group AG1,438$1.00K

Not filed for Q3 2022 yet (1)

Institutions that held Outlook Therapeutics, Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding OTLK in Q2 2022 that haven't filed for Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
Urban Wealth Management, LLC7,473$8.00K